Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection | Zendy

Awewura Kwara | Zendy; Anthony Enimil | Zendy; Fizza S. Gillani | Zendy; Hongmei Yang | Zendy; Anima M. Sarfo | Zendy; Albert Dompreh | Zendy; Antoinette Ortsin | Zendy; Lawrence OseiTutu | Zendy; Sandra Kwarteng Owusu | Zendy; Lubbe Wiesner | Zendy; Jennifer Norman | Zendy; Jaclynn Kurpewski | Zendy; Charles A. Peloquin | Zendy; Daniel Ansong | Zendy; Sampson Antwi | Zendy

Open Access

Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection

Author(s) -

Awewura Kwara,

Anthony Enimil,

Fizza S. Gillani,

Hongmei Yang,

Anima M. Sarfo,

Albert Dompreh,

Antoinette Ortsin,

Lawrence OseiTutu,

Sandra Kwarteng Owusu,

Lubbe Wiesner,

Jennifer Norman,

Jaclynn Kurpewski,

Charles A. Peloquin,

Daniel Ansong,

Sampson Antwi

Publication year - 2015

Publication title -

journal of the pediatric infectious diseases society

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.269

H-Index - 31

eISSN - 2048-7207

pISSN - 2048-7193

DOI - 10.1093/jpids/piv035

Subject(s) - pyrazinamide , ethambutol , medicine , isoniazid , cmax , pharmacokinetics , tuberculosis , dose , coinfection , pharmacology , rifampicin , gastroenterology , human immunodeficiency virus (hiv) , immunology , pathology

Pharmacokinetic data on the first-line antituberculosis drugs using the World Health Organization (WHO) revised dosages for children are limited. We investigated the pharmacokinetics of these drugs in children who were mostly treated with revised dosages.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research